drugset / Trial / NCT04535427

Role of L-Arginine Supplementation in the Treatment of Rheumatoid Arthritis

NCT04535427 ↗

Phase 2 Unknown 144 enrolled RenJi Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

To investigate the role of L-arginine supplementation in the treatment of DMARDs-refractory moderate to severe rheumatoid arthritis

Timeline

Start
2021-01-01
Primary completion
2023-01-01
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ARGININE Small molecule 3 g —
Subject ARGININE Small molecule 5 g —

Indications